Suppr超能文献

60 岁男性套细胞淋巴瘤患者接受利妥昔单抗治疗后出现肾脏肉样瘤样反应。

Sarcoid-Like Reaction in the Kidney Following Rituximab for Mantle Lymphoma in a 60-Year-Old Man.

机构信息

Department of Nephrology, Dialysis, and Transplantation, Université de Sousse, Faculté de Médecine de Sousse, Hôpital Sahloul, Sousse, Tunisie.

Department of Pathology, Université de Sousse, Faculté de Médecine de Sousse, Hôpital Sahloul, Sousse, Tunisie.

出版信息

Am J Mens Health. 2023 Mar-Apr;17(2):15579883231159343. doi: 10.1177/15579883231159343.

Abstract

The sarcoid-like reaction is a rare autoinflammatory disease that can affect lymph nodes or organs but does not meet the diagnostic criteria for systemic sarcoidosis. Several drug classes have been associated with the development of a systemic sarcoid-like reaction, which defines drug-induced sarcoidosis-like reactions and can affect a single organ. Anti-CD20 antibodies (rituximab) have rarely been reported as responsible for this reaction and this adverse effect has mainly been described during the treatment of Hodgkin's lymphoma. We report a unique case of a sarcoid-like reaction complicating rituximab following the treatment of a mantle cell lymphoma and interesting only the kidney. The 60-year-old patient presented with severe acute renal failure 6 months after the end of his r-CHOP protocol and the urgent renal biopsy revealed acute interstitial nephritis rich in granulomas without caseous necrosis. After ruling out other causes of granulomatous nephritis, a sarcoid-like reaction was retained since infiltration was limited to the kidney. The temporal relationship between rituximab administration and the sarcoid-like reaction onset in our patient supported the diagnosis of a rituximab-induced sarcoidosis-like reaction. Oral corticosteroid treatment led to rapid and lasting improvement in renal function. Clinicians should be warned of this adverse effect and regular and prolonged monitoring of renal function should be recommended during the follow-up of patients after the end of treatment with rituximab.

摘要

类肉瘤样反应是一种罕见的自身炎症性疾病,可影响淋巴结或器官,但不符合系统性肉样瘤病的诊断标准。有几类药物与全身性类肉瘤样反应的发生有关,这定义了药物诱导的类肉瘤样反应,并可能影响单个器官。抗 CD20 抗体(利妥昔单抗)很少被报道为导致这种反应的原因,这种不良反应主要在治疗霍奇金淋巴瘤期间描述。我们报告了一例独特的病例,在治疗套细胞淋巴瘤后,利妥昔单抗引起的类肉瘤样反应仅累及肾脏。这名 60 岁患者在结束 r-CHOP 方案后 6 个月出现严重急性肾衰竭,紧急进行的肾脏活检显示富含肉芽肿的急性间质性肾炎,无干酪样坏死。在排除其他肉芽肿性肾炎的原因后,由于浸润仅限于肾脏,保留了类肉瘤样反应的诊断。在我们的患者中,利妥昔单抗给药与类肉瘤样反应发病之间的时间关系支持利妥昔单抗诱导的类肉瘤样反应的诊断。口服皮质类固醇治疗导致肾功能迅速和持久改善。临床医生应该注意到这种不良反应,并建议在利妥昔单抗治疗结束后对患者进行随访期间定期和长期监测肾功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d52/9989380/3c3e55e02c98/10.1177_15579883231159343-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验